March 5, 2009 (FinancialWire) -- Medical technology firm Kensey Nash Corp. (NASDAQ: KNSY) has appointed Michael Celano as its chief financial officer effective March 10.

Most recently, Celano was the managing director for national life sciences practice of Aon. While at Aon, Celano led business development activities in U.S. markets focused on product and clinical trial and D&O enterprise risk.

Celano was formerly a partner with KPMG and Arthur Andersen, holding life science leadership positions in both firms. He later became the CFO for BioRexis Pharmaceutical, a privately held venture-funded company that was acquired by Pfizer in February 2007.

Exton, Pennsylvania-based Kensey Nash provides a range of products into multiple medical markets, primarily sports medicine, spine, and endovascular markets. Many of the products are based on the company's focus on the design, development, manufacturing and processing of absorbable biomaterials.

The company was the inventor and developer of the Angio-Seal vascular closure device, which is licensed to St. Jude Medical.

FinancialWire" ( http://www.financialwire.net ), an independent, proprietary news service of Investrend Communications, Inc., receives no compensation for its news or opinions. Further disclosure is at http://www.investrend.com/articles/secondlevel.asp?level=472 . To contact FinancialWire" write to inquiries@financialwire.net .

Free annual reports for companies mentioned in the news are accessible via http://investrend.ar.wilink.com/?level=279 .

Copyright(C)2009 by financialwire.net, Inc. All rights reserved.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.